Remarks on the Prolactin Hypothesis of Peripartum Cardiomyopathy by Jakob Triebel et al.
April 2017 | Volume 8 | Article 771
OpiniOn
published: 11 April 2017
doi: 10.3389/fendo.2017.00077
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Ken Ho, 
Garvan Institute of Medical 
Research, Australia
Reviewed by: 
Philippe Chanson, 
Université Paris-Sud, France 
Gudmundur Johannsson, 
University of Gothenburg, Sweden 
Mark Molitch, 
University of Northwestern – St. Paul, 
USA
*Correspondence:
Jakob Triebel 
jakob.triebel@gmx.de
Specialty section: 
This article was submitted to 
Pituitary Endocrinology, 
a section of the journal 
Frontiers in Endocrinology
Received: 19 October 2016
Accepted: 29 March 2017
Published: 11 April 2017
Citation: 
Triebel J, Clapp C, 
Martínez de la Escalera G and 
Bertsch T (2017) Remarks on the 
Prolactin Hypothesis of Peripartum 
Cardiomyopathy. 
Front. Endocrinol. 8:77. 
doi: 10.3389/fendo.2017.00077
Remarks on the prolactin Hypothesis 
of peripartum Cardiomyopathy
Jakob Triebel1*, Carmen Clapp2, Gonzalo Martínez de la Escalera2 and Thomas Bertsch1
1 Institute for Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Nuremberg General Hospital, Paracelsus 
Medical University, Nuremberg, Germany, 2 Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), 
Querétaro, México
Keywords: prolactin, vasoinhibins, peripartum cardiomyopathy, prolactin/vasoinhibin axis, bromocriptine, 
16 kDa pRL
A seminal study in 2007 introduced the hypothesis that an antiangiogenic prolactin fragment with 
a molecular mass of 16 kDa is a key pathological mediator of peripartum cardiomyopathy (PPCM) 
(1). The study reported that this fragment is enzymatically generated by the cleavage of full-length 
prolactin with the lysosomal aspartyl protease cathepsin D. Upon excessive generation, possibly due 
to high pituitary prolactin secretion near term or postpartum and an enhanced oxidative micro-
environment, this prolactin fragment would impair myocardial microvascularization and thereby 
contribute to myocardial dysfunction. Accordingly, a new therapy for PPCM was explored using the 
dopamine D2 receptor agonists, cabergoline and bromocriptine. Treatment with bromocriptine is 
currently being evaluated in a multicenter clinical trial (NCT00998556) (2). The concept underlying 
this putative therapy is the inhibition of the generation of the prolactin fragment by substrate deple-
tion, i.e., the inhibition of pituitary prolactin secretion by activation of dopamine D2 receptors in 
lactotropes. PPCM is a rare disease which occurred with a frequency of 1 case/3189 live births and an 
estimated mortality of 1.36–2.05% (confidence interval 0.29–10.8%) from 1990 to 2002 in the United 
States (3). However, the incidence of PPCM seems to be variable, depending on the geographical 
region, ethnic background, and other criteria (4, 5).
Since the initial discovery, several research, case report, and review articles have been published 
(5–10) describing signaling mechanisms mediating the deleterious action of the 16-kDa prolactin 
fragment and supporting the beneficial effects of treatment with dopamine D2 agonists in patients 
with PPCM. However, there are relevant aspects to the proposed pathological mechanism in PPCM 
that are absent in these studies with the consequence of limiting the field by pointing to wrong, or 
incomplete conclusions.
In contrast to what is suggested in most of the PPCM-related literature, the 16-kDa prolactin 
fragment is only one of the several antiangiogenic prolactin fragments derived from prolactin via 
cathepsin D and other proteolytic enzymes. Altogether, these fragments of different molecular 
masses comprise a family of proteins termed vasoinhibins (11, 12). Cathepsin D alone can generate 
four more vasoinhibins by cleaving full-length prolactin at sites other than the one generating the 
16-kDa fragment (13). Three of these cathepsin D-generated vasoinhibin isoforms have documented 
antiangiogenic activity (11, 13)—a notion that should not go unnoticed when studying the 16-kDa 
vasoinhibin isoform as a key pathologic mediator of PPCM. The possible contribution of other 
vasoinhibin isoforms to the pathophysiology of PPCM has neither been investigated nor discussed, 
not to mention the vasoinhibin isoforms generated by other proteolytic enzymes up regulated in 
experimental PPCM, such as matrix metalloproteinases (1, 11).
The term “16 kDa PRL” (referring to prolactin as the precursor of the fragment) that has often been 
used in the PPCM-related literature was updated by the vasoinhibin nomenclature in 2006 (11, 12, 
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14), and this nomenclature has been refined and reevaluated since 
then (15–17). The introduction of the vasoinhibin nomenclature 
was triggered by the recognition that the 16-kDa fragment is not 
the only endogenous prolactin fragment with antiangiogenic 
properties. As their functional and structural features are unique 
and contrast with those of full-length prolactin, it was recognized 
that these fragments are individual hormones and may not bear 
the same designation. In consequence they were collectively 
named “vasoinhibins,” inspired by one of their principal effects, 
the inhibition of blood vessel growth, and control of blood vessel 
function.
Another neglected issue concerns the levels of vasoinhibins 
and the total composition of their isoforms in the circulation 
during healthy and disease states. In the absence of a quantitative 
vasoinhibin assay, neither reference ranges nor levels in disease 
states could be established. Yet, this is required to confirm the 
contribution of the 16-kDa vasoinhibin isoform to the patho-
physiology of PPCM. Higher levels of 16-kDa vasoinhibin would 
be expected at the onset and declining levels during regression 
of PPCM. This also concerns the safety of using dopamine 
agonists to inhibit the generation of vasoinhibins. It should be 
acknowledged that inhibiting vasoinhibin generation constitutes 
an intervention into a complex endocrine axis [the prolactin/
vasoinhibin axis (18)], which could lead to unintended side 
effects. Some of the cardiovascular side effects of bromocriptine 
such as syncope, hypotension, and pleural/pericardial effusion 
could be influenced by a decline of vasoinhibin levels. This is a 
possibility as vasoinhibins feature inhibition of vasodilation and 
vasopermeability (15, 16, 18).
We suggest that whenever the role of the vasoinhibins in 
PPCM is investigated, their serum levels should be evaluated. 
This is possible by an established methodology combining 
immunoprecipitation and western blotting (semi-quantitative) 
(19). Ideally, at some point in the future, a quantitative vasoin-
hibin assay could be developed which should then be used 
to confirm altered levels of vasoinhibin isoforms in PPCM. 
Although dopamine agonists have been used during pregnancy, 
the safety of this intervention should carefully be monitored. 
This is particularly relevant on the background that vasoin-
hibins are pleiotropic hormones which control angiogenesis-
mediated growth in reproductive and non-reproductive organs 
(18); regulate blood vessel growth, vasopermeability, and vaso-
dilation (15, 16); and have non-vascular effects, which include 
stimulation of vasopressin release (20), thrombolytic effects 
(21), and the stimulation of anxiety- and depression-related 
behaviors (22).
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